Evidence map›Paper›PMID 42420640›Full record

ArticleAnnals of hematology2026

Sea-blue histiocytosis and thrombocytopenia successfully treated with an mTORC1 inhibitor: a case report.

Hongmin Li, Jie Ma, Yu Hu, Jingyao Ma, Guoqing Liu, Yunyun Wei, Chao Yang, Runhui Wu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hongmin LiDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No. 56 Nanlishi Road, Xicheng District, Beijing, China.
Jie MaDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No. 56 Nanlishi Road, Xicheng District, Beijing, China.
Yu HuDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No. 56 Nanlishi Road, Xicheng District, Beijing, China.
Jingyao MaDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No. 56 Nanlishi Road, Xicheng District, Beijing, China.
Guoqing LiuDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No. 56 Nanlishi Road, Xicheng District, Beijing, China.
Yunyun WeiDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No. 56 Nanlishi Road, Xicheng District, Beijing, China.
Chao YangDepartment of Pathology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Runhui WuDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No. 56 Nanlishi Road, Xicheng District, Beijing, China. jie_ma2023@163.com.

Funding

National Key Research and Development Program of China 2023UFC2706100
6 · The paper itself

Abstract

This report describes a pediatric patient with acquired sea-blue histiocytosis (SBH) and refractory immune thrombocytopenia (ITP) who harbors a heterozygous variant in TSC2 (p.Arg1713His). The child failed to respond to conventional first-line therapies for ITP but achieved rapid platelet normalization within 1 months of sirolimus initiation. Regression of SBH was observed at 3 months post-treatment. The identification of the TSC2 variant, along with the dramatic resolution of both SBH and thrombocytopenia upon sirolimus therapy, suggests a possible association between TSC2-related mTOR pathway dysregulation, sea-blue histiocytosis, and thrombocytopenia.

Indexed as

Mechanistic Target of Rapamycin Complex 1Purpura, Thrombocytopenic, IdiopathicSirolimusThrombocytopeniaChildHumansTOR Serine-Threonine KinasesTuberous Sclerosis Complex 2 ProteinMechanistic Target of Rapamycin Complex 1SirolimusTOR Serine-Threonine KinasesTuberous Sclerosis Complex 2 ProteinmTORC1Sea-blue histiocytosisThrombocytopeniaTSC2

Identifiers

PMID42420640
PMCPMC13630841

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.